vs
Surgery Partners, Inc.（SGRY）与微博公司（WB）财务数据对比。点击上方公司名可切换其他公司
微博公司的季度营收约是Surgery Partners, Inc.的1.5倍（$1.3B vs $885.0M），微博公司净利率更高（35.7% vs -1.7%，领先37.4%），过去两年微博公司的营收复合增速更高（22.6% vs 11.1%）
Surgery Partners, Inc.（NASDAQ代码：SGRY）旗下的United Surgical Partners International（USPI）是美国领先的日间手术护理服务商，总部位于得克萨斯州达拉斯，由唐·斯廷于1998年创立，专注于为患者提供便捷、高效的门诊外科医疗服务，运营多家合规手术中心，覆盖美国多地医疗需求场景。
微博公司是中国知名的社交网络企业，旗下运营的新浪微博是国内极具影响力的微博客平台，公司总部位于中国北京，为数以亿计的用户提供社交互动、资讯传播、内容创作等多元互联网服务。
SGRY vs WB — 直观对比
营收规模更大
WB
是对方的1.5倍
$885.0M
净利率更高
WB
高出37.4%
-1.7%
两年增速更快
WB
近两年复合增速
11.1%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $885.0M | $1.3B |
| 净利润 | $-15.0M | $458.3M |
| 毛利率 | — | — |
| 营业利润率 | 12.5% | 29.1% |
| 净利率 | -1.7% | 35.7% |
| 营收同比 | 2.4% | — |
| 净利润同比 | 86.2% | — |
| 每股收益（稀释后） | $-0.11 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SGRYWB
| Q4 25 | $885.0M | — | ||
| Q3 25 | $821.5M | $1.3B | ||
| Q2 25 | $826.2M | $841.7M | ||
| Q1 25 | $776.0M | $396.9M | ||
| Q4 24 | $864.4M | — | ||
| Q3 24 | $770.4M | $1.3B | ||
| Q2 24 | $762.1M | $833.4M | ||
| Q1 24 | $717.4M | $395.5M |
净利润SGRYWB
| Q4 25 | $-15.0M | — | ||
| Q3 25 | $-22.7M | $458.3M | ||
| Q2 25 | $-2.5M | $234.8M | ||
| Q1 25 | $-37.7M | $108.1M | ||
| Q4 24 | $-108.5M | — | ||
| Q3 24 | $-31.7M | $297.4M | ||
| Q2 24 | $-15.5M | $164.6M | ||
| Q1 24 | $-12.4M | $51.1M |
营业利润率SGRYWB
| Q4 25 | 12.5% | — | ||
| Q3 25 | 12.9% | 29.1% | ||
| Q2 25 | 13.5% | 30.4% | ||
| Q1 25 | 8.0% | 27.8% | ||
| Q4 24 | 14.7% | — | ||
| Q3 24 | 7.9% | 29.0% | ||
| Q2 24 | 11.1% | 28.2% | ||
| Q1 24 | 10.6% | 25.2% |
净利率SGRYWB
| Q4 25 | -1.7% | — | ||
| Q3 25 | -2.8% | 35.7% | ||
| Q2 25 | -0.3% | 27.9% | ||
| Q1 25 | -4.9% | 27.2% | ||
| Q4 24 | -12.6% | — | ||
| Q3 24 | -4.1% | 22.9% | ||
| Q2 24 | -2.0% | 19.8% | ||
| Q1 24 | -1.7% | 12.9% |
每股收益（稀释后）SGRYWB
| Q4 25 | $-0.11 | — | ||
| Q3 25 | $-0.18 | — | ||
| Q2 25 | $-0.02 | — | ||
| Q1 25 | $-0.30 | — | ||
| Q4 24 | $-0.86 | — | ||
| Q3 24 | $-0.25 | — | ||
| Q2 24 | $-0.12 | — | ||
| Q1 24 | $-0.10 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $239.9M | $1.1B |
| 总债务越低越好 | $3.6B | — |
| 股东权益账面价值 | $1.7B | $3.9B |
| 总资产 | $8.1B | $6.9B |
| 负债/权益比越低杠杆越低 | 2.10× | — |
8季度趋势，按日历期对齐
现金及短期投资SGRYWB
| Q4 25 | $239.9M | — | ||
| Q3 25 | $203.4M | $1.1B | ||
| Q2 25 | $250.1M | $1.2B | ||
| Q1 25 | $229.3M | $1.2B | ||
| Q4 24 | $269.5M | — | ||
| Q3 24 | $221.8M | — | ||
| Q2 24 | $213.5M | $1.9B | ||
| Q1 24 | $185.2M | $2.1B |
总债务SGRYWB
| Q4 25 | $3.6B | — | ||
| Q3 25 | $3.5B | — | ||
| Q2 25 | $3.5B | — | ||
| Q1 25 | $3.4B | — | ||
| Q4 24 | $3.3B | — | ||
| Q3 24 | $3.1B | — | ||
| Q2 24 | $3.0B | — | ||
| Q1 24 | $2.8B | — |
股东权益SGRYWB
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.7B | $3.9B | ||
| Q2 25 | $1.7B | $3.6B | ||
| Q1 25 | $1.7B | $3.5B | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | $1.9B | — | ||
| Q2 24 | $2.0B | $3.4B | ||
| Q1 24 | $2.0B | $3.3B |
总资产SGRYWB
| Q4 25 | $8.1B | — | ||
| Q3 25 | $7.9B | $6.9B | ||
| Q2 25 | $8.0B | $6.5B | ||
| Q1 25 | $7.9B | $6.7B | ||
| Q4 24 | $7.9B | — | ||
| Q3 24 | $7.5B | — | ||
| Q2 24 | $7.5B | $7.1B | ||
| Q1 24 | $7.0B | $7.3B |
负债/权益比SGRYWB
| Q4 25 | 2.10× | — | ||
| Q3 25 | 2.00× | — | ||
| Q2 25 | 1.98× | — | ||
| Q1 25 | 1.98× | — | ||
| Q4 24 | 1.83× | — | ||
| Q3 24 | 1.63× | — | ||
| Q2 24 | 1.56× | — | ||
| Q1 24 | 1.42× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $103.4M | — |
| 自由现金流经营现金流 - 资本支出 | $90.6M | — |
| 自由现金流率自由现金流/营收 | 10.2% | — |
| 资本支出强度资本支出/营收 | 1.4% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $195.6M | — |
8季度趋势，按日历期对齐
经营现金流SGRYWB
| Q4 25 | $103.4M | — | ||
| Q3 25 | $83.6M | — | ||
| Q2 25 | $81.3M | — | ||
| Q1 25 | $6.0M | — | ||
| Q4 24 | $111.4M | — | ||
| Q3 24 | $65.2M | — | ||
| Q2 24 | $82.8M | — | ||
| Q1 24 | $40.7M | — |
自由现金流SGRYWB
| Q4 25 | $90.6M | — | ||
| Q3 25 | $63.8M | — | ||
| Q2 25 | $57.9M | — | ||
| Q1 25 | $-16.7M | — | ||
| Q4 24 | $89.1M | — | ||
| Q3 24 | $45.0M | — | ||
| Q2 24 | $55.9M | — | ||
| Q1 24 | $19.7M | — |
自由现金流率SGRYWB
| Q4 25 | 10.2% | — | ||
| Q3 25 | 7.8% | — | ||
| Q2 25 | 7.0% | — | ||
| Q1 25 | -2.2% | — | ||
| Q4 24 | 10.3% | — | ||
| Q3 24 | 5.8% | — | ||
| Q2 24 | 7.3% | — | ||
| Q1 24 | 2.7% | — |
资本支出强度SGRYWB
| Q4 25 | 1.4% | — | ||
| Q3 25 | 2.4% | — | ||
| Q2 25 | 2.8% | — | ||
| Q1 25 | 2.9% | — | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 2.6% | — | ||
| Q2 24 | 3.5% | — | ||
| Q1 24 | 2.9% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SGRY
| Private Insurance | $460.5M | 52% |
| Government Revenue | $368.6M | 42% |
| Other | $19.8M | 2% |
| Self Pay Revenue | $19.6M | 2% |
| Other Patient Service Revenue Sources | $16.5M | 2% |
WB
| Income from operations | $373.2M | 29% |
| Shares used in computing diluted net income per share attributable to Weibos shareholders | $268.1M | 21% |
| Shares used in computing basic net income per share attributable to Weibos shareholders | $238.6M | 19% |
| Value-added services | $186.1M | 14% |
| Less: Income tax expenses | $113.2M | 9% |
| Investment related income, net | $45.0M | 4% |
| Product development | $16.7M | 1% |
| General and administrative | $10.6M | 1% |
| Sales and marketing | $7.1M | 1% |
| Accretion to redeemable non-controlling interests | $3.0M | 0% |
